Form 4: Xeris Biopharma Holdings Executive Beth Hecht Sells 40,000 Shares

Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, sold 40,000 shares of common stock at an average price of $5.4311 on March 20, 2025.

Summary

• On March 20, 2025, Beth Hecht, the Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., sold 40,000 shares of common stock.
• The sale was executed at a weighted average price of $5.4311 per share.
• The prices for individual transactions ranged from $5.380 to $5.475.
• Following the reported transaction, Hecht directly owns 1,353,510 shares of Xeris Biopharma Holdings, Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports an insider transaction. The sale itself doesn't inherently indicate a positive or negative outlook for the company.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency regarding insider transactions. They do not necessarily indicate a negative outlook for the company.

Stakeholder Impact

• The sale of shares by a company executive could be perceived differently by stakeholders; some may see it as a lack of confidence, while others may view it as a normal part of personal financial management.

Key Dates

Keywords

Xeris Biopharma Holdings, Insider Trading, Form 4, Stock Sale, Beth Hecht, XERS